RxDoctor Payments Data

Jeffrey Arnold, MD

Family Medicine · Waco, TXNPI 1740289800

Payments from drug & device makers

$4,666in general payments, 2019–2025

Across 230 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$596
  • Novo Nordisk$455
  • AbbVie$372
  • Phathom Pharmaceuticals, Inc.$351
  • GSK$211
  • Ironshore Pharmaceuticals Inc.$202
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,63699%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,666 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$97,117
Medicare patients
257
Services billed
1,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin154$169,196
OzempicSemaglutide82$107,292
EliquisApixaban88$73,696
MounjaroTirzepatide27$33,242
JanuviaSitagliptin Phosphate28$33,163
TrulicityDulaglutide21$26,451
FarxigaDapagliflozin Propanediol18$23,782
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$19,991
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$19,790
Breo ElliptaFluticasone/Vilanterol19$10,381
TradjentaLinagliptin13$6,491
Spiriva RespimatTiotropium Bromide12$6,218
Levemir FlexpenInsulin Detemir20$4,630
Colesevelam Hcl12$4,538
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$87$181,906179 claims
Novo NordiskOzempic$455$107,29282 claims
PfizerEliquis$198$73,69688 claims
Lilly USA, LLCMounjaro, Trulicity$168$59,69248 claims
MerckJanuvia$90$33,16328 claims
GSKTrelegy Ellipta, Breo Ellipta$211$30,37244 claims
AstraZenecaFarxiga, Symbicort$596$26,77731 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$2,852300 claims
AbbVieSynthroid$372$1,65819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →